Skip to main content
OpenTrials
Enrolling by invitation

NCT Number: NCT07779551

Comparison of Two Drugs Bupivacaine and Ropivacaine for Postoperative Analgesia in Bilateral Superficial Cervical Plexus Block After Thyroidectomy

There is significant difference between bupivacaine and ropivacaine in terms of postoperative pain assessment in patients undergoing total thyroidectomy with bilateral superficial cervical plexus block.

Enrolling by invitation

Interested in participating?

Request Info

Key information

Age range

20 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Dr Faisal Masood teaching Hospital Sargodha

Sargodha, Punjab Province, 40100, Pakistan

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age range:20-40 years.
  • Both male and female individuals.
  • Patients classified as American Society of Anesthesiologists (ASA)I-II.
  • Patients scheduled for elective total thyroidectomy under general anesthesia

Exclusion criteria

  • Patient Refusal
  • Hypothyroidism,Hyperthyroidism,Retrosternal goiter
  • Premedication with preoperative analgesics
  • Excessive alcohol intake,Electrolyte imbalance
  • Pregnancy or lactation
  • Coagulation disorders
  • Additional surgical intervention

Treatment and study plan

Group 1 will receive 10ml of 0.25% bupivacaine

Procedure

After placing the patients in a supine position with the neck slightly extended and rotated away from the side to be blocked,the procedure will be performed under sterile aseptic conditions.The sternocleidomastoid muscle will be identified,and a high-frequency (1O MHz) linear probe will be positioned transversely over the muscle,between the mastoid and clavicle. The cutaneous nerves of the cervical plexus,visible as round hypoechoic structures in the fascial plane beneath the muscle,will be targeted using a 22-gauge short block needle (5 cm) inserted in-plane with the transducer. Negative aspiration will be performed during injection to avoid inadvertent intravascular delivery. An emergency crash cart will remain available throughout the procedure.

Group 2 will receive 10ml of 0.25% ropivacaine on each side.

Procedure

After placing the patients in a supine position with the neck slightly extended and rotated away from the side to be blocked,the procedure will be performed under sterile aseptic conditions.The sternocleidomastoid muscle will be identified,and a high-frequency (1O MHz) linear probe will be positioned transversely over the muscle,between the mastoid and clavicle. The cutaneous nerves of the cervical plexus,visible as round hypoechoic structures in the fascial plane beneath the muscle,will be targeted using a 22-gauge short block needle (5 cm) inserted in-plane with the transducer. Negative aspiration will be performed during injection to avoid inadvertent intravascular delivery. An emergency crash cart will remain available throughout the procedure

Primary outcomes

  1. Postoperative pain

    Time frame: 24 hours post surgery

  2. time to the first request for analgesia

    Time frame: 24 hours postoperatively

  3. Block-related complications

    Time frame: immediately after the intervention/procedure

Sponsors and collaborators

Lead sponsor

Sargodha Medical College

Other

Registry information

Official study title

Comparison of Postoperative Analgesia Using Bupivacaine vs Ropivacaine With Bilateral Superficial Cervical Plexus Block After Thyroidectomy

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Aug 21, 2026
Registry last updated
Aug 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.